Take a look at some of Wednesday's midday movers:
Avon moved lower after the manufacturer of beauty products said it halted a rollout of new order management system. The company said a pilot program in Canada resulted in "significant business disruption in that market".
Autohome, the owner of Chinese auto websites, rose as much as 83 percent in its market debut, after being priced at $17 a share.
Valero Energy Partners jumped more than 20 percent in its market debut. The company is an oil and gas pipeline operator formed by refining giant Valero Energy.
Boeing moved lower. The union representing its Seattle machinists said its leaders had met with top execs of the airplane maker about restarting talks on the company's new 777X jetliner.
Pandora lost ground after rival Spotify announced that it will offer its streaming music service in another 20 countries starting this week and confirmed it will offer a free version of its service for mobile phones and tablets. In addition, Spotify signed an exclusive deal that will bring Led Zeppelin's back catalogue to the streaming service.
Lab Corp tumbled after the company's 2014 earnings guidance missed expectations. The medical testing services provider sees tepid demand and an uncertain healthcare environment. Rival Quest Diagnostics fell in sympathy.
Costco slipped after the retailer's first quarter profit missed Wall Street estimates due to lower gas prices and weak foreign currencies.
Joy Global moved lower after the mining equipment maker forecast 2014 earnings below analysts' estimates.
Delta fell despite comments at an investor meeting that profits were rising and debt was lower for 2013.
Curtiss-Wright rose after guiding fiscal 2014 revenues above expectations.
Ruby Tuesday lost ground after it said reports suggesting it hired Goldman Sachs to evaluate strategic alternatives did not come from the company.
Barnes & Noble slipped on news Chairman Leonard Riggio sold 2 million shares at $13.81 in a private block trade.
Lululemon lost ground. Its incoming CEO Laurent Potdevin, will be paid a base salary of $900,000, more than the $706,000 outgoing CEO Christine Day made in base salary in 2013.
Avanir plunged after the company said its experimental drug to reduce pain in patients with multiple sclerosis failed in a mid-stage trial. Avanir also reported fourth-quarter results that fell shy of Wall Street estimates.
—By CNBC's Rich Fisherman.
Questions? Comments? Email us at marketinsider@cnbc.com